Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selvita Announces Changes to Management Board

Published: Wednesday, November 06, 2013
Last Updated: Wednesday, November 06, 2013
Bookmark and Share
Company announces appointment of Dr. Miroslawa Zydron and Dr. Krzysztof Brzozka.

Selvita has announced the appointment of Dr. Mirosława Zydron to the position of Member of the Management Board, Director of Chemistry Division and Dr. Krzysztof Brzozka to the position of Executive Vice President, Chief Scientific Officer.

As of 5 November 2013, the Management Board of Selvita includes the following members:
• Paweł Przewięźlikowski - Chief Executive Officer,
• Bogusław Sieczkowski - Executive Vice President, Chief Operating Officer,
• Krzysztof Brzózka - Executive Vice President, Chief Scientific Officer,
• Miłosz Gruca - Member of the Management Board, Director of Biology Department
• Sebastian Kwaśny - Member of the Management Board, Director of Bioinformatics Department
• Mirosława Zydroń - Member of the Management Board, Director of Chemistry Division

The new appointments follow the extension of the scale of company’s operations, and are aimed at strengthening the new members' responsibility for the results of their departments, respectively the Chemistry Services Division and internal R&D pipeline, as well as facilitate their contacts with the current and future Selvita's business partners.

Mirosława Zydron will be responsible for further stable development of Chemistry Services Division strengthening Selvita’s market position and building long-term relationships within the pharmaceutical, biotech, chemical and agrochemical environments.

Krzysztof Brzozka will be responsible for supervision of current internal projects aimed at the development of novel small molecule therapies both in currently established and future strategic collaborations with commercial partners, further development of the department and initiation of new research projects with both industrial and academic partners, strengthening international position of Selvita and to building both research and business relationships with pharmaceutical companies, academic institutions and investors.

Pawel Przewiezlikowski, the Chief Executive Officer of Selvita commented: “We are extremely happy with Krzysztof’s and Miroslawa’s performance. Our R&D division, headed by Krzysztof is progressing dynamically our multiple early stage programs in oncology, CNS and autoimmune disorders and has recently delivered two pre-clinical candidates in our Pim and CDK8 kinase programs. Krzysztof has also been instrumental in forging of our two co-discovery alliances with H3 Biomedicine and Merck Serono.

Mirka’s (Miroslawa’s) Chemistry Services Division has also been expanding rapidly, delivering successful projects to our existing customers from the innovative and generic pharma industry as well as starting new relationships in pharma, chemicals and agrochemicals markets in the USA, Europe and Asia.

We welcome the extended scope of responsibility of both colleagues and look forward to their continued building of exceptional value for our business partners, shareholders and employees.”

“Since 2009, the Chemistry Division at Selvita, with our skills, experience, professionalism, flexibility and openness to the needs of our customers, has won their trust and worked on differentiated projects covering a broad range of chemistries and scientific approaches. Our current goal is to constantly grow in a stable way and further strengthen our market position in the area of R&D outsourcing, through continuous acquisition and ongoing development of highly skilled specialists, development of infrastructure and ensuring the highest quality of service, thus building long-term relationships with our clients in the pharmaceutical, biotechnology, chemical and agrochemical businesses.” said Dr. Mirosława Zydron.

"The ultimate aim of our internal research and development activities is the development of breakthrough therapies in areas such as cancer or Alzheimer's disease. Since its inception, Selvita created a unique in Central and Eastern Europe both in terms of scale and skills team of specialists that joined their efforts to develop first and best in class therapies which are guided by the current high standards of personalized medicine and the requirements of safety and effectiveness of new therapies. We sincerely hope that the intellectual property developed so far and the first-in-class molecules developed by our team will confirm their effectiveness in clinical trials, not only changing the lives of patients struggling with incurable diseases, but also allowing continued growth of the company and value for shareholders, as well as further development of the biotechnology sector in Poland" said Dr. Krzysztof Brzozka.

Dr Miroslawa Zydron joined Selvita in December 2009, and has been responsible for the formation and organization of the Chemistry Services Division, strategic development of the chemistry research services, presentation of the company's offer and building relationships with international clients from the pharmaceutical, biotechnology, chemical and agrochemical environments, as well as overseeing the ongoing projects to ensure the highest quality of services.

Dr. Zydron gained her experience in project management, formation of research and development structures and management of R&D teams in international organizations both in the scientific environment and Pliva company (then: Barr Pharmaceuticals, TEVA), as Head of R&D Laboratory, overseeing analytical and preformulation activities at the stage of drug form development and packaging processes in pilot production in GMP environment.

Dr. Zydron graduated from the Silesian Technical University (Poland), with MSc and PhD Degree in chemistry. Her PhD Thesis gained distinction from Academy of Sciences, Committee of Analytical Chemistry, for the best doctoral thesis in the area of analytical chemistry in Poland in 2004 - 2005. In 2009, she completed a two-year MBA Program at the Rotterdam School of Management at Erasmus University in Rotterdam (Netherlands).

Dr Krzysztof Brzozka joined Selvita in 2007 as a specialist responsible for evaluation, due diligence and in-licensing of research projects. In 2009 he became a Project Manager of the first anticancer project initiated at Selvita and in subsequent years initiated further research projects, also in additional therapeutic indications. In January 2012 he was appointed to the position of Chief Scientific Officer and Member of the Management Board and is currently responsible for development of internal pipeline of novel, small molecule therapies across various indications.

Dr. Brzozka holds a PhD degree from Ludwig Maximilian University in Munich (Germany) and an MSc degree in Biotechnology, specializing in Molecular Biology, from the Jagiellonian University in Krakow (Poland). He also completed a two-year Executive MBA at Stockholm University School of Business and the Cracow University of Economics Business School.

In the years 2003 - 2007, Dr. Brzozka conducted research at the Ludwig Maximilian University in the field of intracellular signaling, pathogen defense mechanisms leading to the immune system inhibition and the innate immune response.

Dr. Brzozka has unique interdisciplinary expertise in development of projects in the preclinical phase, ranging from in silico studies, medical chemistry and, in vitro and in vivo molecular biology studies and toxicology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selvita Establishes its UK Subsidiary in Cambridge
New office will be responsible for supporting the ongoing projects for the UK and Northern Ireland customers.
Thursday, May 07, 2015
Selvita Initiates IND-enabling Studies for its First-In-Class PIM/FLT3 Inhibitor
Company has signed agreement with Aptuit for the preparation of selected studies for the IND/CTA data package.
Saturday, April 04, 2015
Selvita Expands its Proteomics Services Offer
Expansion includes highly sophisticated mass spectrometers, additional ultra HPLC systems; and microscale thermophoresis measurement devices.
Wednesday, March 25, 2015
Selvita Group Received a GMP Certificate
Certificate was issued for 3 years.
Wednesday, February 19, 2014
Selvita Extends Collaboration with Chiesi Farmaceutici
Collaboration started with fee-for-service chemical synthesis in 2011.
Monday, January 13, 2014
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program
Selvita is responsible for early research on the program.
Monday, July 02, 2012
Selvita Signs Contract with Evestra
Delivery of a range of drug metabolism, pharmacokinetic and physicochemical studies.
Tuesday, September 27, 2011
Selvita Signs a Computational Chemistry Services Agreement with IPD, USA
Agreement aims to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD.
Wednesday, April 06, 2011
Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus
The project is aimed to deliver Rottapharm Madaus a set of designed and synthesized compounds having therapeutic potential in an indicated area.
Thursday, July 22, 2010
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!